Senate panel advances bipartisan bill to lower drug prices amid GOP blowback

Senate panel advances bipartisan bill to lower drug prices amid GOP blowback
© Greg Nash

The Senate Finance Committee on Thursday voted to advance a bipartisan deal to lower drug prices to the full Senate, though nine Republicans voted against the measure. 

All Democrats on the panel supported the deal between Sens. Chuck GrassleyCharles (Chuck) Ernest GrassleyGOP senators call for Barr to release full results of Epstein investigation Trump health official: Controversial drug pricing move is 'top priority' Environmental advocates should take another look at biofuels MORE (R-Iowa) and Ron WydenRonald (Ron) Lee WydenWyden calls for end to political ad targeting on Facebook, Google Ex-CIA chief worries campaigns falling short on cybersecurity Overnight Energy: Trump sparks new fight over endangered species protections | States sue over repeal of Obama power plant rules | Interior changes rules for ethics watchdogs MORE (D-Ore.), leading to a final vote of 19-9. 

ADVERTISEMENT
The large number of GOP defections doesn't bode well for the likelihood of Senate Majority Leader Mitch McConnellAddison (Mitch) Mitchell McConnellSocial media never intended to be in the news business — but just wait till AI takes over Ex-CIA chief worries campaigns falling short on cybersecurity Two-thirds of Americans support assault weapons ban: Fox News poll MORE (R-Ky.) bringing the bill up for a vote in the full Senate, at least not without substantial changes.

The bill would impose a limit on drug price increases in Medicare’s prescription drug program, called Part D, by forcing drug companies to pay money back if their prices rise faster than inflation. 

Many Republican senators opposed this provision as a price control that violates GOP free-market orthodoxy, and therefore opposed the larger package. 

“I’ve heard from Iowans who have left prescriptions at the pharmacy counter or who skipped doses of their medicine to save money,” Grassley said, adding, “This is the moment for the Senate to act.”

Sen. Pat ToomeyPatrick (Pat) Joseph ToomeyNSA improperly collected US phone records in October, new documents show Overnight Defense: Pick for South Korean envoy splits with Trump on nuclear threat | McCain blasts move to suspend Korean military exercises | White House defends Trump salute of North Korean general WH backpedals on Trump's 'due process' remark on guns MORE (R-Pa.) led the effort to strike from the bill the limit on price increases, an amendment that failed on a tie vote of 14-14, with just two Republicans, Grassley and Sen. Bill CassidyWilliam (Bill) Morgan CassidyWashington takes historic step forward on paid parental leave The 23 Republicans who opposed Trump-backed budget deal On The Money: Fed poised to give Trump boost with rate cut | Parties unable to reach deal in Trump tax return lawsuit | New York opens investigation into Capital One data breach MORE (R-La.), voting in favor of keeping the provision.  

“We should not use this sledgehammer of a universal Part D price control,” Toomey said. 

Sen. John CornynJohn CornynThe Hill's Morning Report — Trump and the new Israel-'squad' controversy O'Rourke says he will not 'in any scenario' run for Senate O'Rourke says Trump 'terrorizing' immigrants in campaign relaunch speech MORE (R-Texas) voted for the overall package but also objected to the limit on Medicare price increases. 

“This bill is not anywhere near action on the floor,” Cornyn said. “It’s more important that we get it right than that we get it done fast.”

The advancement of the measure was a rare loss for the powerful pharmaceutical industry, which denounced the bill. But there is a long road ahead with plenty of opportunities for the industry to stop the bill on its way to the full Senate. 

Democrats all supported the package but said more needed to be done. They pushed for an amendment that would allow Medicare to negotiate drug prices, which has been a Democratic priority.

All Republicans voted to defeat that amendment, while all Democrats except Sen. Bob MenendezRobert (Bob) MenendezHouse passes temporary immigration protections for Venezuelans Senate panel advances bipartisan bill to lower drug prices amid GOP blowback Democrats pledge to fight Trump detention policy during trip to border MORE (N.J.), voted in favor.

House Democrats are working on a rival drug pricing bill that would allow Medicare to negotiate drug prices, removing a clause in current law that prevents Medicare from directly interfering in drug prices. 

Asked about the GOP objections to his bill, Grassley told reporters after the vote Thursday that Republicans should realize the Grassley-Wyden bill is more moderate than a potential deal between President TrumpDonald John TrumpWarren unveils Native American policy plan Live-action 'Mulan' star spurs calls for boycott with support of Hong Kong police Don't let other countries unfairly tax America's most innovative companies MORE and Speaker Nancy PelosiNancy PelosiThe Hill's Morning Report — Trump and the new Israel-'squad' controversy Trump crosses new line with Omar, Tlaib, Israel move Pelosi: Israel's Omar-Tlaib decision 'a sign of weakness' MORE (D-Calif.) would be. 

“You've got the president campaigning on doing away with the noninterference clause, who knows what he's going to do at the last minute,” Grassley told reporters. “If he would join forces with Pelosi, look at what that would do to everything that we Republicans stand for in the United States Senate.”

“It seems to me that the Grassley-Wyden approach is a very moderate approach to what could come out,” he added. “There's got to be a realization on the part of Republicans about that and there ought to be a realization on the part of pharmaceutical companies where they would be if we had the noninterference clause go away.”